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1. Introduction
Biological interactions between drugs or their metabolites and 
proteins are of relevance in connection with the knowledge of the 
cellular activity and with the biochemical paths involved in some 
medical conditions.[1] Specifically, binding of drugs or their 
metabolites to transport proteins such as serum albumins (SAs) 
or 1-acid glycoproteins (AAGs) determines aspects such as 
activity, distribution, toxicity or excretion rate of these 
ligands.[2] Besides, when metabolites are present simultaneously 
with the parent drugs, it is also relevant to investigate whether 
this situation results in modification of some aspects of drug 
behavior.[3]  
A number of studies have been devoted to the binding of 
drugs and metabolites to serum proteins using different 
approaches. Hence, in vitro techniques have been the most 
employed for this purpose. They include radiometry, surface 
plasmon resonance, nuclear magnetic resonance and fluorescence 
spectroscopies, calorimetry, crystallography, equilibrium 
dialysis, ultrafiltration, ultracentrifugation, chromatography or 
capillary electrophoresis. In parallel, in silico tools allow accurate 
predictions of the configuration of the protein binding site, by 
analyzing the thermodynamically most favored configurations. 
Remarkably, the use of in vitro results as a starting point for 
application of computational tools, results in an optimized 
characterization of the metabolite-protein interactions and of the 
nature and structural characteristics of the binding sites.[4] 
In this context, the development of tools for investigating 
metabolite-protein binding remains of great interest. A possibility 
is the use of a combined methodology that employs laser flash 
photolysis (LFP) as in vitro technique together with docking and 
molecular dynamics simulation studies as in silico tools.  
To prove the concept, we selected as metabolites the two 
demethylated derivatives (MCPZ and DCPZ) of the anti-
psychotic agent chlorpromazine (CPZ), a drug employed over 
decades for the treatment of schizophrenia. [5] Their chemical 




Transient absorption spectroscopy in combination with in silico methods has been employed to 
study the interactions between human serum albumin (HSA) and the anti-psychotic agent 
chlorpromazine (CPZ) as well as its two demethylated metabolites (MCPZ and DCPZ). Thus, 
solutions containing CPZ, MCPZ or DCPZ and HSA (molar ligand:protein ratios between 1:0 
and 1:3) were submitted to laser flash photolysis and the ΔAmax value at λ = 470 nm, 
corresponding to the triplet excited state, was monitored. In all cases, the protein-bound ligand 
exhibited higher ΔAmax values measured after the laser pulse and were also considerably 
longer-lived than the non-complexed forms. This is in agreement with an enhanced 
hydrophilicity of the metabolites, due to the replacement of methyl groups with H that led to a 
lower extent of protein binding. For the three compounds, laser flash photolysis displacement 
experiments using warfarin or ibuprofen indicated Sudlow site I as the main binding site. 
Docking and molecular dynamics simulation studies revealed that the binding mode of the two 
demethylated ligands with HSA would be remarkable different from CPZ, specially for DCPZ, 
which appears to come from the different ability of their terminal ammonium groups to stablish 
hydrogen bonding interactions with the negatively charged residues within the protein pocket 
(Glu153, Glu292) as well as to allocate the methyl groups in an apolar environment. DCPZ 
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structures are shown in Chart 1. Since MCPZ and DCPZ 
maintain the CPZ chromophore unaltered, any possible 
modulation of the biological behavior should be correlated with 
the nature of the aminoalkyl side-chain. In particular, 
biotransformation could lead to a modified affinity to transport 
proteins, leading to a different bioavailability.  
The absorption spectra of CPZ shows the UV–Vis features 
typical of the phenothiazine chromophore, reaching the UVA 
zone; in MeCN, the fluorescence maximum is located at max = 
451 nm. [6] The transient absorption spectrum in MeCN displays 
a maximum at max = 470 nm, attributed to the first triplet excited 
state, [7] while in PBS, the main maximum appears at λ = 525 
nm, and is ascribed to CPZ radical cation (CPZ●+). [8] The 
transient absorption spectra of MCPZ and DCPZ in aqueous 
medium (PBS, air), display contributions from the radical cation 
and the triplet excited state. For the parent drug and the two 
metabolites, the triplet lifetime (T) values, monitored λ = 470 
nm, were lower than 1 s and increased with the methylation 
degree. [7b] 
Chart 1. Chemical structures of CPZ, MCPZ and DCPZ. 
As protein, we selected human serum albumin (HSA) the most 
abundant transport protein in plasma, responsible for carrying 
endogenous or exogenous agents in the bloodstream. Binding of 
drugs and metabolites to HSA can enhance or decrease drug’s 
performance, since the unbound fraction is generally the one that 
exhibits pharmacological effect and may be metabolized and/or 
excreted. The human serum albumin (HSA) structure consists of 
a single chain of 585 amino acids containing only one tryptophan 
(Trp) residue; the secondary structure is made by 67% of α helix 
of six turns; the three-dimensional structure is described in terms 
of three domains, each of them constituted in turn by two 
subdomains. [9] In general, small organic molecules bind 
primarily to high-affinity sites, with association constant values 
in the range of 104-106 M-1. The pioneering work of Sudlow and 
coworkers, based on displacement of fluorescence probes, 
showed that a considerable number of drugs bind with high 
affinity to site I and site II. [10]  
Interaction of CPZ with HSA and bovine serum albumin 
(BSA) has been investigated in the past using equilibrium 
dialysis, gel filtration or fluorescence quenching. It has been 
described that binding occurs mainly to one site, with an affinity 
constant in the range of 104-105 M-1. [11] However, no 
information about binding of CPZ metabolites is available, 
although characterization of such metabolite-protein interactions 
would be very useful for a better understanding of the 
biochemical pathways involved in various biological conditions. 
[12] Different methodologies have been employed to investigate
binding of metabolites to proteins; they involve either
examination of the protein-bound metabolites or determination of
the free concentrations of these species. [13] The former
approach is of course preferable and provides deeper insight into
the nature of the binding process.
The properties of triplet excited states result to be markedly 
medium-dependent; in this context, they can be excellent 
reporters to investigate compartmentalized microenvironments, 
including the protein binding pockets. [14]. We have previously 
shown that the behavior of triplet excited states of ligands within 
transport proteins (such as1-acid glycoproteins or serum 
albumins), monitored by transient absorption spectroscopy, 
constitutes a powerful tool to examine drug binding. [15] 
The methodology could also be applied to compare the protein 
binding behavior of a given drug and its metabolites. Thus, CPZ 
and their demethylated metabolites could be suitable candidates 
to explore this methodology, given the possibility of generating 
and monitoring their triplet excited states. Moreover, upon 
encapsulation, formation triplet excited states could be favored 
over generation of ionic species (such as radical ions) within the 
protein binding sites, as previously observed for other ligands. 
[16] Finally, the protein microenvironment could also protect the
encapsulated ligands, resulting in an enhanced photosafety, as
described for the HSA binding of cinacalcet; under these
conditions, this drug is protected from attack by oxygen and from
the phototoxic effects produced by singlet oxygen formation.
[15e]
The aim of the present work is to compare binding of CPZ 
and its two demethylated metabolites MCPZ and DCPZ to HSA 
by monitoring the triplet excited state of the three compounds by 
transient absorption spectroscopy. Although the metabolites 
maintain the same chromophore as parent CPZ, they should 
exhibit an enhanced hydrophilicity due to the replacement of 
methyl groups with H, leading to a lower extent of protein 
binding. The obtained results confirm these expectations and are 
in full agreement with theoretical calculations. 
2. Results and Discussion
2.1. Synthesis 
The two metabolites MCPZ and DCPZ were obtained using 
procedures previously described in the literature. [17] Thus, 
synthesis of MCPZ was carried out in two steps by treatment of 
CPZ with 1-chloroethyl chloroformate followed by reaction with 
MeOH (Scheme 1A), while DCPZ was obtained by reduction of 
3-(2-chloro-10H-phenothiazin-10-yl) propanenitrile with LiAlH4 
[18] (Scheme 1B).
Scheme 1. Synthesis of MCPZ (A) and DCPZ (A). Reagents and conditions: (a) ethyl 
formate, DCM, 0 ºC. (b) MeOH, reflux. (c) LiAlH4, THF, reflux.  
2.2. Photophysical Studies 
As expected, the absorption spectra of CPZ, MCPZ and 
DCPZ in PBS were very similar, with maxima at ca. 254 y 305 
nm (Supplementary Material, Figure S1); in the presence of 
HSA, a slight bathochromic shift was observed (Figure S2).  
The parent drug and the two metabolites displayed a weak 
fluorescence in PBS, under nitrogen, centered at 453 nm (Figure 
S3). In all cases, the F values were lower than 0.01 (3.6 × 10
-3 
for CPZ, 4.3 × 10-3 for MCPZ and 7.6 × 10-3 for DCPZ). In the 
presence of HSA (Figure S4), the emission maxima did not shift 
significantly, but the band was somewhat more intense, (F = 6.4 
× 10-3, 6.9 × 10-3 and 8.4 × 10-3 for CPZ, MCPZ and DCPZ, 
respectively). 
The triplet excited states of CPZ, MCPZ and DCPZ were 
then used as reporters for the microenvironments experienced 
within HSA. Laser flash photolysis of the three compounds was 
performed at λexc = 308 nm, in 0.01 M PBS, under aerobic 
atmosphere. Figures 1A-C show the spectra obtained 0.2 s after 
the laser pulse in the presence and absence of HSA. Remarkably, 
the band peaking at 470 nm, corresponding to the triplet excited 
state, was much more prominent in the presence of HSA than in 
aqueous solution, especially in the case of the parent drug. 
A complete set of transient spectra for CPZ, MCPZ and 
DCPZ, both alone and in the presence of HSA, at different delay 
times are provided in the Supplementary Material (Figure S5). 
These data are consistent with the coexistence of the triplet 
excited state (maximum at  = 470 nm) and the radical cation 
(maximum at 530 nm) of the drug and its metabolites under all 
conditions, with the formed species being much longer lived in 
the presence of protein. 
Figure 1. Laser flash photolysis of CPZ (A), MCPZ (B) and DCPZ (C) at exc = 308 
nm, in PBS, air. Spectra obtained 0.2 s after the laser pulse in the absence (black trace) 
or presence (red trace) of 2 equivalents of HSA.  
Non-covalent binding was then monitored by following the 
enhancement of the Amax value at  = 470 nm in the presence 
of increasing quantities of HSA. For that purpose, a battery of 
PBS solutions containing CPZ, MCPZ or DCPZ and HSA 
(molar ratios between 1:0 and 1:3) were prepared and monitored 
by laser flash photolysis. In all cases, the protein-bound ligand 
decays exhibited higher Amax value and were considerably 
longer than those of the non-complexed forms (Figures 2A-C, 
under air); see Figure S6 for the case of CPZ under nitrogen. The 
parent drug CPZ exhibited the highest affinity towards HSA, as 
indicated by the fact that the 3CPZ* signal, almost negligible in 
PBS, clearly increased after addition of only 0.5 equivalents of 
HSA.  
Figure 2. Laser flash photolysis of CPZ (A), MCPZ (B) and DCPZ (C) at exc = 308 
nm, in PBS, air. Decays monitored at 470 nm in the presence of different amounts of 
HSA 
Then, the binding of CPZ, MCPZ or DCPZ to HSA was 
compared, using data obtained from transient absorption 
spectroscopy experiments. Hence, the plot of Amax/A0 value at 
 = 470 nm vs HSA concentration showed that the parent drug
displays higher affinity for the protein than the two metabolites;
this is in agreement with its more lipophilic nature (Figure 3). In
the three cases, the binding constants were found to be in the 104-
105 range, with CPZ > MCPZ > DCPZ (see Figure S7 for an
estimation based on treatment of the Amax/A0 data). This
constitutes a straightforward methodology to determine the
relative binding of a drug and its metabolites to a given protein.
Laser flash photolysis measurements were then performed 
using displacement probes, warfarin (WAR) for site I and 
ibuprofen (IBU) for site II, to elucidate the binding site of CPZ, 
MCPZ and DCPZ within HSA Thus, addition of WAR to a  
Figure 3. Relative binding of CPZ, MCPZ or DCPZ to HSA, calculated from the 
Amax value at  = 470 nm in the presence of increasing amounts of HSA. 
CPZ/HSA mixture led to a significant decrease of the Amax 
value at  = 470 nm (Figure 4A), indicating displacement of the 
initially bound drug from the binding site I to the bulk solution. 
However, addition of IBU to the CPZ/HSA mixture did not 
result in important changes of Amax at 470 nm (Figure 4A). A 
similar trend was observed for MCPZ and DCPZ (Figures 
4B,C). This is consistent with preferential binding of the three 
investigated compounds to site I. 
Figure 4. Laser flash photolysis of CPZ (A), MCPZ (B) and DCPZ (C) at exc = 308 
nm, in PBS, air. Decays monitored at 470 nm in the presence of site I (WAR) or and site 
II (IBU) probes. Concentration of ligand was 8 × 10-5 M. Molar ratios are indicated in 
parenthesis. 
2.3. Computational Studies 
In an effort to get a better understanding in atomic detail of 
the differences experimentally obtained in the affinity of CPZ 
and its two metabolites, MCPZ and DCPZ, to HSA, molecular 
docking studies were first carried out. These studies were 
performed using GOLD 5.2.2 [19] program and the protein 
coordinates found in the crystal structure of HSA in complex 
with oxyphenbutazone [4-butyl-1-(4-hydroxyphenyl)-2-
phenylpyrazolidine-3,5-dione] (PDB entry 2BXB [20]). Among 
the available crystallographic structures of HSA with a ligand in 
drug-binding site Sudlow I [10] (sub-domain IIA), the latter was 
chosen because the arrangement of oxyphenbutazone in 2BXB 
might be in some extend close to the expected for the tricyclic 
moiety of CPZ. This drug has two benzene rings joined by a 
central six-membered ring. An analysis of the binding pocket 
revealed that Sudlow I is a large spherical and amphiphilic 
pocket located in the vicinity of the sole tryptophan residue in 
HSA (Trp214). Thus, half of the pocket is mainly lipophilic as it 
is composed by apolar residues (Leu238, Ala261, Ile264, Ile290, 
Ala291, Leu260, Leu219, Phe223, etc.) and the second half is 
polar as it contains mainly four polar residues, specifically 
Arg257, Tyr150, His242 and Lys199.  
Taking into account that the QM/MM (Quantum 
Mechanics/Molecular Mechanics) calculations reported by 
Phuangsawai et al. [21] revealed that Lys199, His242 and 
Arg257 are involved in the esterease activity of HSA and that 
this enzymatic activity involves the neutral Lys199 residue as 
nucleophile, a neutral protonation state of this residue was 
considered in these computational studies. Lys199 has an 
unusually low pKa of ∼8 allowing its chemical modification by 
compounds such as trifluoromethyl-substituted aryl halides and 
sulfonates. [22] In addition, as CPZ and its two metabolites 
contain a propylamine chain, which would be protonated at 
physiological pH, the protonated forms of the ligands were also 
employed.  
On the other hand, taking into account that proteins undergo 
conformational changes during ligand recognition (induced-fit 
model) that are not taken into account in docking studies (key-
lock model) because the protein is considered as a rigid mold, 
Molecular Dynamics (MD) simulation studies were subsequently 
performed with the highest score solution obtained by docking. 
This type of more complex computational studies: (i) avoids false 
positives, since the ligands that are not stable in the identified 
pocket will be expelled from this position; and (ii) provides a 
more realistic model of the protein/ligand complex. To this end, 
the GOLD-proposed binding modes of CPZ and its two 
metabolites were further validated by MD simulation studies. 
These studies were performed for 100 ns by using the monomer 
of the CPZ@HSA, MCPZ@HSA and DCPZ@HSA protein 
complexes obtained by docking in a truncated octahedron of 
water molecules obtained with the molecular mechanics force 
field AMBER. [23]  
2.3.1. Binding Mode of CPZ 
Our computational studies showed that CPZ would be 
anchored to Sudlow site I of HSA by a strong hydrogen bonding 
interaction between the flexible ammonium moiety of the ligand 
and the carboxylate group of Glu153 (Figure 5). This interaction 
was observed during about 60% of the simulation with an 
average value of the distance of 2.9 Å (Figure S8). The 
arrangement of the aromatic ring in CPZ in this sub-pocket 
would be driven by a strong cation-п interaction between the 
guanidinium group of Arg257 and the ring containing the 
chlorine atom. 
Figure 5. Proposed Binding mode of CPZ. (A) Overall view of the CPZ@HSA complex obtained by MD simulation studies. Snapshot after 40 ns is shown. The main 
backbone of CPZ is shown as red spheres. The domains I−III and sub-domains (A,B) in HSA protein are labelled. The localization of the ligand in site I is highlighted with 
a pale yellow background. (B) Relevant interactions of CPZ with sub-domain IIA (site I) of HSA. Hydrogen bonding and cation-п interactions between the ligand and the 
protein are shown as red and black dashed lines and highlighted with a yellow and blue background, respectively. Relevant side chain residues are shown and labelled. 
Figure 6. Proposed Binding mode of MCPZ and DCPZ. (A−B) Overall views of the MCPZ@HSA (A) and DCPZ@HSA (B) complexes obtained by MD simulation studies. 
Snapshots after 90 ns and 80 ns, respectively, are shown. The main backbone of MCPZ and DCPZ are shown as orange and purple spheres, respectively. (C) Comparison of the binding 
mode of CPZ, MCPZ and DCPZ. Note how the binding mode of DCPZ is significantly different from CPZ and MCPZ. (D−E) Relevant interactions of MCPZ (D) and DCPZ (E) with 
HSA. Hydrogen bonding interactions between the ligands and the protein are shown as red dashed lines and highlighted with a yellow background. Relevant side chain residues are 
shown and labelled. 
In addition, the aromatic moiety of the ligand would establish 
numerous favorable lipophilic interactions with the side chain of 
residues Leu238, Ala261, Ile264, Leu283, Ile290, Ala291, 
Leu260, Leu219, and Trp214. Both methyl groups in CPZ would 
interact with the side chain of Ala291 (strong) as well as the 
carbon side chain of Lys195 (weaker). Therefore, the position of 
the ammonium group would be fixed on one face by hydrogen 
bonding with Glu153 and on the other face with lipophilic 
interactions with Lys195 (carbon chain) and Ala91.  
2.3.2. Binding Mode of the Two Metabolites 
The computational studies performed with the two 
demethylated ligands, MCPZ and DCPZ, revealed that the 
binding mode of these ligands with HSA would be remarkable 
different from the aforementioned for CPZ (Figures 6A−C). As 
expected, the keys of the distinct arrangement of CPZ in relation 
to MCPZ and DCPZ appears to come from the different ability 
of their terminal ammonium groups (−NH+Me2, −NH2
+Me, 
−NH3
+, respectively) to establish hydrogen bonding interactions
with the negatively charged residues within the protein pocket, as
well as to allocate the methyl groups in an apolar environment.
Thus, for MCPZ, the interaction of the methyl group with the
side chain of Ala291, which was present in CPZ, would be lost.
As a result, MCPZ would bind to HSA by locating its aromatic
ring at the entrance of Sudlow site I but without being able to
immerse this moiety in this pocket as for CPZ (Figure 6D). As
for CPZ, the main polar interaction would be between the
ammonium group and the carboxylate group of Glu153. This
hydrogen bonding interaction was observed during about 67% of
the simulation with an average value of the distance of 2.9 Å
(Figure S9).
Moreover, DCPZ would be rotated 180º in relation to CPZ 
locating the aromatic ring away from the Sudlow site I of HSA 
and sole tryptophan residue in HSA (Trp214). The driving force 
of this ligand rotation appears to be the formation of two strong 
hydrogen bonds, instead of one as in CPZ and MCPZ, between 
its ammonium group (−NH3
+) and the carboxylate groups of 
residues Glu153 and Glu292 (Figure 6E). on top of the These 
hydrogen bonding interactions were identified during about 84% 
and 90%, respectively, of the simulation with average values of 
2.9 Å for both cases (Figure S10). Moreover, our docking studies 
revealed that CPZ would have the highest binding affinity 
(scoring) of the three ligands and DCPZ the lowest one. Thus, the 
ranking affinity would be CPZ > MCPZ > DCPZ, which is in 
agreement with the experimental results. 
As regards the lack of radical cation formation inside HSA, as 
evidenced by the laser flash photolysis results, computational 
studies suggest that it would be caused by an increase in the 
planarity of the tricyclic ring as well as the methylene group 
directly connected to it. Thus, Joshi et al. [5c] reported that the 
calculated butterfly angle increases from 145.4º in CPZ to 157.4º 
in CPZ●+. The larger planarity of the aromatic ring and the 
subsequent conformational changes in the flexible chain would 
prevent a deep anchoring of this ring into the apolar sub-pocket 
as it occurs with CPZ (Figure 7). 
3. Conclusions
Thus, it can be concluded that transient absorption 
spectroscopy in combination with docking and molecular 
dynamics simulation studies constitutes a powerful tool to study 
binding of drug metabolites to transport proteins. The triplet state 
decay is a sensitive indicator that clearly discriminates between 
the free and protein-bound species. In addition, the lipophilic 
microenvironment existing in the protein cavities favors triplet 
formation over generation of ionic species such as radical 
cations. Docking and Molecular Dynamics simulation studies 
revealed that the binding mode of the two demethylated ligands 
within HSA would be remarkable different from that of CPZ, 
specially for DCPZ, which appears to come from the different 
ability of their terminal ammonium groups to stablish hydrogen 
bonding interactions with the negatively charged residues within 
the protein pocket (Glu153, Glu292) as well as to allocate the 
methyl groups in an apolar environment. DCPZ would be rotated 
180º in relation to CPZ locating the aromatic ring away from the 
Sudlow I of HSA. 
Figure 7. Comparison of the binding mode of CPZ (blue) and CPZ●+ (light 
orange) with HSA predicted by MD simulation studies. Snapshots after 40 ns and 
90 ns, respectively, are shown. Note how the increased planarity of the tricyclic 
ring in CPZ●+ would prevent the interaction of aromatic ring with the deep apolar 
pocket of sub-domain IIA (site I). 
4. Experimental Section
4.1. General 
Chlorpromazine hydrochloride (CPZ·HCl), 3-(2-chloro-10H-
phenothiazin-10-yl)propanonitrile, 1-chloroethyl chloroformate 
(ACE-Cl), human serum albumin (HSA), guanidium chloride 
(GndCl), lithium aluminium hydride (LiAlH4), warfarin (WAR) 
and ibuprofen (IBU) were commercially available. Solvents 
(methanol, 2-butanone, tetrahydrofuran, chloroform) and 
hydrochloric acid were analytical grade. Phosphate buffer saline 
solutions (PBS, 0.01 M, pH = 7.4) were obtained by dissolving 
commercially available phosphate-buffered saline tablets in 
deionized water. NMR spectra were recorded on a Bruker AV 
400 spectrometer at 296K. Chemical shifts are referenced to 
tetramethylsilane (δ = 0 ppm). HRMS were obtained by 
electrospray mass spectroscopy in the positive mode using a 
Xevo QTof MS apparatus (Waters). 
4.2. Synthesis of the Metabolites 
4.2.1. Synthesis of MCPZ [17] 
To a well stirred solution of CPZ in methylene chloride at 
0ºC, ACE-Cl (0.720 ml, 6.7 mmol) was slowly added. Then, the 
reaction mixture was maintained under reflux for 1h. The solvent 
was evaporated, the solid was dissolved in diethyl ether (50 mL) 
and washed with water. The organic layer was dried (MgSO4), 
filtered and the solvent removed. The intermediate 3-(2-chloro-
10H-phenothiazine-10-yl) was used without further purification. 
It was then dissolved in methanol and maintained under reflux 
for 45 min. The solvent was evaporated and MCPZ was obtained 
by crystallization with 2-butanone, in 88% yield. 1H-RMN (400 
MHz, CD3OD),  (ppm 7.22 – 7.29 (m, 1H), 7.19 (dd, J1 = 7.7 
Hz, J2 = 1.4 Hz, 1H), 7.14 (d, J = 8.2 Hz, 1H), 7.04 – 7.10 (m, 
2H), 7.01 (ddd, J1 = 10.2 Hz, J2 = 7.8 Hz, J3 = 1.5 Hz, 2H), 4.08 
(t, J = 6.4 Hz, 2H), 3.09 (dd, J1 = 9.1 Hz, J2 = 6.9 Hz, 2H), 2.63 
(s, 3H), 2.15 (tt, J1 = 12.7, J2 = 6.4 Hz, 2H); 
13C-RMN (100 
MHz, CD3OD) (, ppm148.0, 145.7, 134.7, 129.3, 129.0, 
128.7, 127.1, 126.2, 124.7, 124.0, 117.6, 117.4, 48.2, 45.1, 33.7, 
24.7; HRMS calcd. for C16H17N2SCl: 304.0801 [M-HCl], found 
304.07881. 
4.2.1. Synthesis of DCPZ [18] 
3-(2-chloro-10H-phenothiazin-10-yl)propanonitrile (200 mg, 
0.70 mmol) was placed in a soxhlet and extracted with THF 
containing LiAlH4 (61 mg, 1.61 mmol). The reaction was 
stopped adding 5 mL of 20% NaOH aqueous solution. Inorganic 
salts were removed by filtration and the solvent was extracted 
with THF. The organic layer was dried over MgSO4. After 
addition of some drops of HCl, the solvent was evaporated. The 
hydrochloride salt of DCPZ was obtained by crystallization with 
ethanol, with 35%. 1H-RMN (300 MHz, CD3OD),  (ppm 7.25 
(ddd, J1 = 8.2 Hz, J2 = 7.3 Hz, J3 = 1.5 Hz, 1H), 7.18 (dd, J1 = 
7.7, J2 = 1.5 Hz, 1H), 7.13 (d, J = 8.2 Hz, 1H), 7.04 – 7.10 (m, 
2H), 6.95 – 7.04 (m, 2H), 4.08 (t, J = 6.4 Hz, 2H), 2.98 – 3.09 
(m, 2H), 2.13 (dq, J1 = 14.2, J2 = 6.3 Hz, 2H); 
13C-RMN (75 
MHz, CDCl3) , ppm148.0, 145.7, 134.7, 129.3, 128.92, 
128.6, 127.0, 126.1, 124.6, 123.9, 117.6, 117.4, 45.2, 38.6, 26.0.  
4.3. Fluorescence Experiments 
Emission spectra were recorded using a JASCO FP-8500 
spectrofluorometer system, provided with a monochromator in 
the wavelength range 200–850 nm. Fluorescence of the samples 
was registered after adjusting their absorbance below to 0.2 at the 
excitation wavelength (λexc= 330 nm). The quartz cells employed 
were 1 cm path length and 4 mL of capacity. Measurements were 
performed at room temperature.
4.4. Laser Flash Photolysis Experiments 
Laser flash photolysis (LFP) measurements were performed 
using a pulsed Xe/HCl excimer laser (exc= 308 nm, 30 mJ per 
pulse). A pulsed Xe lamp was employed as detecting light 
source. The LFP device consisted of a pulsed laser, a Xe lamp, a 
monochromator and a photomultiplier. The output signal from 
the oscilloscope was transferred to a personal computer. Kinetic 
traces were monitored at  = 470 nm. Absorbance of the samples 
was kept below 0.3 at the excitation wavelength. The quartz cells 
employed were 1 cm path length and 4 mL of capacity. 
Measurements were performed at room temperature.
4.5. Docking Studies 
They have been performed using GOLD 5.2.2 program [19] 
and the protein coordinates from the crystal structure of HSA in 
complex with oxyphenbutazone [4-butyl-1-(4-hydroxyphenyl)-2-
phenylpyrazolidine-3,5-dione] (PDB entry 2BXB [20]). The 
experimental procedure used was similar to that described in [21] 
for ligand 4-(4-trifluorometylphenyl)phenol. 
4.6. Molecular Dynamics Simulations Studies 
The ligand minimization (CPZ, MCPZ and DCPZ), the 
generation and minimization of CPZ@HSA, MCPZ@HSA and 
DCPZ@HSA binary complexes and MD simulation of the 
resulting minimized complexes (100 ns) were carried following 
the protocol described in [21] for ligand 4-(4-
trifluorometylphenyl)phenol. The ligand/protein structures herein 
disclosed have been created using the molecular graphics 
program PyMOL.[22] For the analysis of the trajectories and the 
rmsd of the protein during the simulation calculated the cpptraj 
module in AMBER 16 was employed.[23]. 
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Appendix A. Supplementary Material 
Absorption and fluorescence spectra of CPZ, MCPZ and 
DCPZ in the absence and presence of HSA; laser flash 
photolysis of spectra od CPZ, MCPZ and DCPZ at different 
delay times in the absence or presence of HSA, modified 
Benessi-Hildebrand plots and variation of the relative distances 
for selected atoms in ligand@protein complexes. 
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